SAM
SGMO

Symphony Asset Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Symphony Asset Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-16,769
Closed -$318K – 285
2018
Q1 		$318K Buy
+16,769
New +$358K 0.04% 290

Other funds holding SGMO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Symphony Asset Management's SGMO Position: Q2 2018 in Review

Symphony Asset Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2018, closing a stake of 16,769 shares — an estimated $318K sold.

Symphony Asset Management first reported a position in SGMO in Q1 2018 and held it in 1 quarter. The position peaked at $318K in Q1 2018. 210 funds tracked by Wall St. Rank hold SGMO as of Q2 2018.

  • Symphony Asset Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2018 after selling out during the quarter.
  • Symphony Asset Management sold 16,769 SANGAMO THERAPEUTICS INC shares in Q2 2018, an estimated $318K.
  • Symphony Asset Management first reported a position in SANGAMO THERAPEUTICS INC in Q1 2018 and held it in 1 quarter.
  • Symphony Asset Management's SANGAMO THERAPEUTICS INC position peaked at $318K in Q1 2018.
  • 210 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2018.

Based on Symphony Asset Management's 13F filing for Q2 2018, filed 14 Aug 2018.